Date Filed | Type | Description |
12/19/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/17/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
12/23/2021 |
4
| HENWOOD GERALDINE (President and CEO) has filed a Form 4 on Baudax Bio, Inc.
Txns:
| Paid exercise price by delivering 18,636 shares
@ $0.31, valued at
$5.8k
Granted 821,168 options to buy
@ $1.7, valued at
$1.4M
|
|
12/14/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
09/23/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/17/2021 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
05/10/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
04/22/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
04/15/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
01/22/2021 |
4
| HENWOOD GERALDINE (President and CEO) has filed a Form 4 on Baudax Bio, Inc.
Txns:
| Granted 65,435 shares
@ $0 |
|
01/20/2021 |
4
| HENWOOD GERALDINE (Director) has filed a Form 4 on Recro Pharma, Inc.
Txns:
| Paid exercise price by delivering 6,816 shares
@ $3.03, valued at
$20.7k
Exercised 5,000 restricted stock units
@ $0 |
|
01/05/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
12/09/2020 |
4
| HENWOOD GERALDINE (President and CEO) has filed a Form 4 on Baudax Bio, Inc.
Txns:
| Paid exercise price by delivering 11,732 shares
@ $1.14, valued at
$13.4k
Paid exercise price by delivering 71,283 shares
@ $1.14, valued at
$81.3k
|
|
12/09/2020 |
4
| HENWOOD GERALDINE (President and CEO) has filed a Form 4 on Recro Pharma, Inc.
Txns:
| Paid exercise price by delivering 34,128 shares
@ $2.3, valued at
$78.5k
|
|
04/20/2020 |
4/A
| HENWOOD GERALDINE (President and CEO) has filed a Form 4 on Recro Pharma, Inc.
Txns:
| Sold 80,000 shares
@ $8.22, valued at
$657.6k
Exercised 80,000 options to buy
@ $2.47, valued at
$197.6k
|
|
04/20/2020 |
4
| HENWOOD GERALDINE (President and CEO) has filed a Form 4 on Recro Pharma, Inc.
Txns:
| Sold 80,000 shares
@ $8.22, valued at
$657.6k
|
|
01/29/2020 |
4
| HENWOOD GERALDINE (President and CEO) has filed a Form 4 on Baudax Bio, Inc.
Txns:
| Exercised 19,070 shares
@ $0 Paid exercise price by delivering 5,051 shares
@ $8.51, valued at
$43k
|
|
01/22/2020 |
4
| HENWOOD GERALDINE (President and CEO) has filed a Form 4 on Recro Pharma, Inc.
Txns:
| Paid exercise price by delivering 5,552 shares
@ $16.38, valued at
$90.9k
Exercised 5,000 restricted stock units
@ $0 |
|
01/03/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
12/09/2019 |
4
| HENWOOD GERALDINE (President and CEO) has filed a Form 4 on Recro Pharma, Inc.
Txns:
| Granted 93,550 shares
@ $0 |
|
12/09/2019 |
4
| HENWOOD GERALDINE (President and CEO) has filed a Form 4 on Baudax Bio, Inc.
Txns:
| Granted 195,387 shares
@ $0 Granted 128,571 shares
@ $0 Granted 183,673 options to buy
@ $6.33, valued at
$1.2M
|
|
11/12/2019 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
06/11/2019 |
4
| HENWOOD GERALDINE (Director) has filed a Form 4 on TETRAPHASE PHARMACEUTICALS INC
Txns:
| Granted 16,500 options to buy
@ $0.77, valued at
$12.7k
|
|
05/15/2019 |
4
| HENWOOD GERALDINE (President and CEO) has filed a Form 4 on Recro Pharma, Inc.
Txns:
| Sold 123,500 shares
@ $8.89, valued at
$1.1M
Sold 21,306 shares
@ $8.8886, valued at
$189.4k
Exercised 123,500 options to buy
@ $2.47, valued at
$305k
|
|
02/19/2019 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
02/14/2019 |
5
| Form 5 - Annual statement of changes in beneficial ownership of securities: |
01/23/2019 |
4
| HENWOOD GERALDINE (President and CEO) has filed a Form 4 on Recro Pharma, Inc.
Txns:
| Granted 35,801 shares
@ $0 Paid exercise price by delivering 1,425 shares
@ $7.99, valued at
$11.4k
Granted 171,184 options to buy
@ $7.99, valued at
$1.4M
Exercised 5,000 restricted stock units
@ $0 |
|
01/04/2019 |
4
| HENWOOD GERALDINE (President and CEO) has filed a Form 4 on Recro Pharma, Inc.
Txns:
| Paid exercise price by delivering 4,223 shares
@ $7.41, valued at
$31.3k
|
|
01/04/2019 |
4
| HENWOOD GERALDINE (President and CEO) has filed a Form 4 on Recro Pharma, Inc.
Txns:
| Paid exercise price by delivering 4,223 shares
@ $7.41, valued at
$31.3k
|
|
06/01/2018 |
4
| HENWOOD GERALDINE (Director) has filed a Form 4 on TETRAPHASE PHARMACEUTICALS INC
Txns:
| Granted 12,500 options to buy
@ $3.68, valued at
$46k
|
|
01/22/2018 |
4
| HENWOOD GERALDINE (President and CEO) has filed a Form 4 on Recro Pharma, Inc.
Txns:
| Paid exercise price by delivering 1,575 shares
@ $8.89, valued at
$14k
Exercised 5,000 restricted stock units
@ $0 |
|
01/04/2018 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
10/02/2017 |
4
| HENWOOD GERALDINE (President and CEO) has filed a Form 4 on Recro Pharma, Inc.
Txns:
| Exercised 31,100 shares
@ $0 Paid exercise price by delivering 9,794 shares
@ $9.04, valued at
$88.5k
|
|
06/01/2017 |
4
| HENWOOD GERALDINE (Director) has filed a Form 4 on TETRAPHASE PHARMACEUTICALS INC
Txns:
| Granted 12,500 options to buy
@ $6.89, valued at
$86.1k
|
|
|